GlassScriptPhysician profile
David A Lockshaw
NPI 1396728523
$1,662.60
in general payments reported to CMS, 2019-2025
28 companies · $719 in 2025
The $719 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.89 · 2020: $51.03 · 2021: $70.24 · 2022: $154 · 2023: $118 · 2024: $490 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $226.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $179.89 | 2024-2025 | |
| Pfizer INC. | $151.39 | 2019-2025 | |
| Corcept Therapeutics | $123.37 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $119.25 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.35 | 2022-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $85.31 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $69.56 | 2024-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $65.34 | 2025 | Auvelity |
| Amarin Pharma, INC. | $63.74 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $60.56 | 2022-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $35.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.76 | 2021 | |
| Lundbeck LLC | $32.33 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $31.81 | 2025 | Gardasil 9, Capvaxive |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.65 | 2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2025 | Elaprase |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.88 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.68 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $25.90 | 2019-2021 | |
| Si-Bone, INC. | $18.85 | 2023 | |
| Glaxosmithkline, LLC. | $17.59 | 2023 | Trelegy Ellipta |
| Shield Therapeutics INC | $17.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.96 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $15.08 | 2025 | |
| Sumitomo Pharma America, INC. | $14.78 | 2024 | Gemtesa |
| Vivus LLC | $14.72 | 2025 | Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lockshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.